Regeneron Pharmaceuticals Inc. buy marge
Summary
This prediction ended on 23.11.21 with a price of €570.00. The BUY prediction by marge finished with a performance of 7.75%. marge has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -0.509% | -0.509% | 39.818% | 89.606% |
iShares Core DAX® | 1.056% | 1.056% | 18.108% | 16.006% |
iShares Nasdaq 100 | -1.886% | -0.160% | 26.970% | 36.233% |
iShares Nikkei 225® | 2.553% | 4.359% | 17.676% | 10.955% |
iShares S&P 500 | -0.434% | 0.224% | 24.986% | 37.667% |
Comments by marge for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
(Der Cocktail war eine von drei pharmazeutischen Behandlungen, die Trump zur Behandlung von COVID-19 im Oktober verabreicht wurden.)
Dies ist das zweite Antikörpermedikament, das in diesem Monat für die Notfallzulassung bei COVID-19-Patienten zugelassen wurde, nachdem Eli Lilly am 09.11. von der FDA eine Notfallgenehmigung für Bamlanivimab erhalten hat, eine Behandlung für leichtes bis mittelschweres COVID-19 bei erwachsenen und kindlich und jugendlichen Patienten.
In the thread Trading Regeneron Pharmaceuticals Inc.